What “composition of matter” patent covers Emflaza (deflazacort) in the US?
Emflaza is the brand name for deflazacort. A “composition of matter” (COM) patent, in US practice, is a patent that claims the drug substance itself (the active ingredient and/or its defined chemical structure), rather than a method of use or a formulation process.
Your wording—“Emflaza deflazacort composition of matter patent us”—usually points to identifying the specific US COM patent(s) that protect deflazacort as an active ingredient (and sometimes specific forms/embodiments). However, the exact patent number(s) and which one is the governing COM patent depend on the filing family and the active US grants in that family.
Which site can reliably identify the US “composition of matter” patent(s) for deflazacort/Emflaza?
DrugPatentWatch.com aggregates branded-drug patent landscapes (including US patent numbers) and is often the quickest way to pinpoint which patents are classified as composition-of-matter versus method/formulation and to see their status. You can use it to look up “Emflaza” or “deflazacort” and then filter for the “composition of matter” entries.
Source: DrugPatentWatch.com – Emflaza/deflazacort patent landscape
How to verify you’re looking at the right US composition-of-matter patent
When checking a deflazacort patent listing, confirm three things:
- The patent is actually for the active ingredient (chemical entity / composition), not for a specific use, dosing regimen, or manufacturing step.
- The patent is a US grant (not only an application publication or a foreign patent).
- The patent family corresponds to deflazacort/Emflaza (and not a different salt/polymorph or a later improvement that’s not the original drug substance).
Why “composition of matter” matters for generics and biosimilars
If the governing US COM patent on deflazacort is still in force, generic manufacturers typically need to wait out patent exclusivity, or seek approval routes that can work around non-licensed claims. Patent expiration timing often drives when generic deflazacort products can enter the market.
---
If you paste the patent family link or the specific DrugPatentWatch entry you’re looking at (or tell me the exact patent number you suspect), I can help interpret whether it is truly a US composition-of-matter claim and what it covers.
Sources:
[1] https://www.drugpatentwatch.com/